Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Ophthotech Corp    OPHT

Delayed Quote. Delayed  - 05/31 09:59:59 pm
53.7 USD   +5.01%
05/31 OPHTHOTECH CORP : to Present at the Goldman Sachs 37th Annual Global..
05/18 OPHTHOTECH : What to Look for in These Biotech Stocks? Threshold Pha..
05/04 OPHTHOTECH : reports 1Q loss
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 
The feature you requested does not exist. However, we suggest the following feature:

Ophthotech Corporation : to Present at the Goldman Sachs 37th Annual Global Healthcare Conference

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/31/2016 | 01:31pm CEST

- Webcast Available Through Ophthotech Website –

Ophthotech Corporation (NASDAQ:OPHT) announced today that David R. Guyer, M.D., Chief Executive Officer and Chairman of the Board, will present at the Goldman Sachs 37th Annual Global Healthcare Conference in Rancho Palos Verdes, California on Tuesday June 7, 2016 at 8:40 a.m. PT (11:40 a.m. ET).

Investors and the general public are invited to listen to a live webcast of the presentation at www.ophthotech.com. Please connect to Ophthotech’s website several minutes prior to the start of the presentation to ensure adequate time for any software download that may be necessary. A replay will be available for 14 days following the presentation.

About Ophthotech Corporation

Ophthotech is a biopharmaceutical company specializing in the development of novel therapeutics to treat back of the eye diseases, with a focus on developing innovative therapies for age-related macular degeneration (AMD). Ophthotech's most advanced product candidate, Fovista® anti-PDGF therapy, is in Phase 3 clinical trials for use in combination with anti-VEGF therapy that represents the current standard of care for the treatment of wet AMD. Ophthotech's second product candidate, Zimura®, an inhibitor of complement factor C5, is being developed for the treatment of geographic atrophy, a form of dry AMD, and in combination with anti-VEGF therapy in wet AMD patients. For more information, please visit www.ophthotech.com.

Forward-looking Statements

Any statements in this press release about Ophthotech's future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Any forward-looking statements represent Ophthotech's views only as of the date of this press release. Ophthotech anticipates that subsequent events and developments will cause its views to change. While Ophthotech may elect to update these forward-looking statements at some point in the future, Ophthotech specifically disclaims any obligation to do so.

OPHT-G


© Business Wire 2016
share with twitter share with LinkedIn share with facebook
share via e-mail
0
React to this article
Latest news on OPHTHOTECH CORP
05/31 OPHTHOTECH CORPORATION : to Present at the Goldman Sachs 37th Annual Global Heal..
05/18 OPHTHOTECH : What to Look for in These Biotech Stocks? Threshold Pharma, Seattle..
05/12 OPHTHOTECH : Carmen A. Puliafito, MD, MBA, Former Dean of Keck School of Medicin..
05/12 OPHTHOTECH : Reports First Quarter 2016 Financial and Operating Results
05/09 OPHTHOTECH CORP. : Change in Directors or Principal Officers (form 8-K)
05/04 OPHTHOTECH : reports 1Q loss
05/04 OPHTHOTECH : Reports First Quarter 2016 Financial and Operating Results
05/04 OPHTHOTECH : Reports First Quarter 2016 Financial and Operating Results
04/28 OPHTHOTECH : Carmen A. Puliafito, MD, MBA, Former Dean of Keck School of Medicin..
04/26 OPHTHOTECH CORPORATION : to Report First Quarter 2016 Financial Results and Host..
Advertisement
News chart
Full-screen chart
Income Statement Evolution
More Financials